Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain/ACE2 Complex*
- PMID: 33174669
- PMCID: PMC8284874
- DOI: 10.1002/cbic.202000562
Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain/ACE2 Complex*
Abstract
Infection and replication of SARS CoV-2 (the virus that causes COVID-19) requires entry to the interior of host cells. In humans, a protein-protein interaction (PPI) between the SARS CoV-2 receptor-binding domain (RBD) and the extracellular peptidase domain of ACE2 on the surface of cells in the lower respiratory tract is an initial step in the entry pathway. Inhibition of the SARS CoV-2 RBD/ACE2 PPI is currently being evaluated as a target for therapeutic and/or prophylactic intervention. However, relatively little is known about the molecular underpinnings of this complex. Employing multiple computational platforms, we predicted "hot-spot" residues in a positive-control PPI (PMI/MDM2) and the CoV-2 RBD/ACE2 complex. Computational alanine scanning mutagenesis was performed to predict changes in Gibbs' free energy that are associated with mutating residues at the positive control (PMI/MDM2) or SARS RBD/ACE2 binding interface to alanine. Additionally, we used the Adaptive Poisson-Boltzmann Solver to calculate macromolecular electrostatic surfaces at the interface of the positive-control PPI and SARS CoV-2/ACE2 PPI. Finally, a comparative analysis of hot-spot residues for SARS-CoV and SARS-CoV-2, in complex with ACE2, is provided. Collectively, this study illuminates predicted hot-spot residues, and clusters, at the SARS CoV-2 RBD/ACE2 binding interface, potentially guiding the development of reagents capable of disrupting this complex and halting COVID-19.
Keywords: ACE2; COVID-19; SARS CoV-2; computational alanine scanning mutagenesis; hot spots; protein-protein interactions.
© 2020 Wiley-VCH GmbH.
Figures
Update of
-
Computational Hot-Spot Analysis of the SARS-CoV-2 Receptor Binding Domain / ACE2 Complex.bioRxiv [Preprint]. 2020 Aug 6:2020.08.06.240333. doi: 10.1101/2020.08.06.240333. bioRxiv. 2020. Update in: Chembiochem. 2021 Apr 6;22(7):1196-1200. doi: 10.1002/cbic.202000562. PMID: 32793900 Free PMC article. Updated. Preprint.
References
-
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I, Research T, N Engl J Med 2020, 382, 727–733; - PMC - PubMed
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL, Nature 2020, 579, 270–273. - PMC - PubMed
-
- Gallagher TM, Buchmeier MJ, Virology 2001, 279, 371–374; - PMC - PubMed
- Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P, Proc Natl Acad Sci U S A 2004, 101, 4240–4245; - PMC - PubMed
- Song W, Gui M, Wang X, Xiang Y, PLoS Pathog 2018, 14, e1007236; - PMC - PubMed
- Li F, Li W, Farzan M, Harrison SC, Science 2005, 309, 1864–1868. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
